StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Trading Down 3.8 %
LPCN opened at $5.07 on Friday. The firm has a market cap of $26.97 million, a price-to-earnings ratio of -1.66 and a beta of 1.05. Lipocine has a 12 month low of $2.31 and a 12 month high of $7.15. The stock has a fifty day moving average price of $4.53 and a 200-day moving average price of $3.52.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $0.22 million during the quarter. On average, equities research analysts forecast that Lipocine will post -1.49 EPS for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- The Most Important Warren Buffett Stock for Investors: His Own
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to Buy Cheap Stocks Step by Step
- Merger or Not, Albertson’s Companies is a Good Buy
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
